Drugs News and Research

RSS

NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.

30 Sep 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

Progressive Medical updates 2010 Drug Spend Analysis

Progressive Medical, Inc. announced today the release of a mid-year update to its 2010 Drug Spend Analysis. This report, which supplements the report released in April, provides clients with an update in workers' compensation medication spending from January 2010 through June 2010 and key factors that affect future expenditures, including inflation, utilization and product mix.

30 Sep 2010

Prix Galien USA committee honors life saving innovations

The Prix Galien USA committee honored innovations that are saving lives last night during the Prix Galien Awards Gala. The Pro Bono Humanum Award, the Prix Galien USA 2010 and the Prix Galien International were presented and related accomplishments celebrated.

30 Sep 2010

Jiangbo fourth-quarter revenues decrease 5.9% to $29.3M

Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced financial results for its fourth quarter and fiscal year ended June 30, 2010. The Company's annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission and is available on the Company's website.

30 Sep 2010

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.

30 Sep 2010

New approach to prevent psychotic symptoms

New research has linked psychosis with an abnormal relationship between two signalling chemicals in the brain. The findings, published in tomorrow's edition of the journal Biological Psychiatry, suggest a new approach to preventing psychotic symptoms, which could lead to better drugs for schizophrenia.

30 Sep 2010

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

The pharmaceutical division of the company Neuron BPh and the research group of Organometallic Chemistry and Homogeneous Catalysis of the Universitat Jaume I, have evaluated the possible applications of a series of ruthenium compounds for their future use in the treatment of neurodegenerative disease such as Alzheimer.

30 Sep 2010

Multi-disciplinary approach increases breast cancer survival rate: Study

Advances in screening for disease detection, better surgical techniques available to more women, and an increased number of therapies that reduce the risk of relapse in patients with both locally advanced and early stage disease, have collectively contributed to dramatic improvements in breast cancer's survival rates, according to a review of 60 years of patient records at The University of Texas MD Anderson Cancer Center.

30 Sep 2010

Canadian Cancer Society alarmed by government inaction to establish national catastrophic drug insurance program

A large majority of Canadians - 85 per cent - say if they were diagnosed with cancer the cost of drugs would have a negative impact on their personal finances, according to poll results released today by the Canadian Cancer Society.

30 Sep 2010

Two new techniques to identify dissolved cocaine in bottles of wine or rum

In two landmark studies published today in the journal Drug Testing and Analysis (DTA), UK and Swiss research teams reveal two techniques proven to identify dissolved cocaine in bottles of wine or rum. These tools will allow customs officials to quickly identify bottles being used to smuggle cocaine, without the need to open or disturb the container.

30 Sep 2010

Study suggests drugs targeting glutamatergic transmission may help treat psychotic illness

There is growing evidence that two neurotransmitters dopamine and glutamate are abnormal in people with psychotic illness, including schizophrenia. Among many other things, these chemicals play a role in cognitive functions, such as memory, learning, and problem solving.

30 Sep 2010

Genotoxic impurities in prescription drugs

Drug manufacturers have been adjusting to strict new government standards that limit the amount of potentially harmful impurities in medicine, according to the cover story of the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine. The impurities are "genotoxic," capable of damaging the DNA in genes.

30 Sep 2010

Dyax, CMIC enter agreement to develop and commercialize DX-88 for HAE treatment

Dyax Corp. and CMIC Co., Ltd, announced today an agreement to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE) and other angioedema indications in Japan.

30 Sep 2010

Scientists use NMR technology to improve protein purification in drug development

The purification of drug components is a large hurdle facing modern drug development. This is particularly true of drugs that utilize proteins, which are notoriously difficult to separate from other potentially deadly impurities. Scientists within the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer Polytechnic Institute are using nuclear magnetic resonance (NMR) to understand and improve an important protein purification process.

30 Sep 2010

ASU receives grant to unravel membrane proteins in host-pathogen interaction

Arizona State University has been awarded a $7.7 million grant for the next five years from the National Institute of General Medical Sciences, part of the National Institutes of Health, to unravel the structures of membrane proteins that play a key role in protection against infectious diseases.

30 Sep 2010

Researchers explain why obesity is resistant to treatment

New research provides evidence of the vicious cycle created when an obese individual overeats to compensate for reduced pleasure from food.Obese individuals have fewer pleasure receptors and overeat to compensate, according to a study by University of Texas at Austin senior research fellow and Oregon Research Institute senior scientist Eric Stice and his colleagues published this week in The Journal of Neuroscience.

30 Sep 2010

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

Three grants totaling more than $4.5 million, from agencies of the National Institutes of Health, will be used to explore novel treatment strategies for muscular dystrophy.

30 Sep 2010

Triple negative breast cancer patients with BRCA gene mutations have low risk of recurrence: Research

Patients with triple negative breast cancer that also have mutations in the BRCA gene appear to have a lower risk of recurrence, compared to those with the same disease without the deleterious genetic mutation, according to researchers at The University of Texas MD Anderson Cancer Center.

30 Sep 2010

MicroRNAs assay may allow better targeted therapy for lung cancer patients

A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.

30 Sep 2010

Drugs News and Research

NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Progressive Medical updates 2010 Drug Spend Analysis

Prix Galien USA committee honors life saving innovations

Jiangbo fourth-quarter revenues decrease 5.9% to $29.3M

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

New approach to prevent psychotic symptoms

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

Multi-disciplinary approach increases breast cancer survival rate: Study

Canadian Cancer Society alarmed by government inaction to establish national catastrophic drug insurance program

Two new techniques to identify dissolved cocaine in bottles of wine or rum

Study suggests drugs targeting glutamatergic transmission may help treat psychotic illness

Genotoxic impurities in prescription drugs

Dyax, CMIC enter agreement to develop and commercialize DX-88 for HAE treatment

Scientists use NMR technology to improve protein purification in drug development

ASU receives grant to unravel membrane proteins in host-pathogen interaction

Researchers explain why obesity is resistant to treatment

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

Triple negative breast cancer patients with BRCA gene mutations have low risk of recurrence: Research

MicroRNAs assay may allow better targeted therapy for lung cancer patients

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News